Administration of Dehydroepiandrosterone Sulfate Retards Onset but not Progression of Autoimmune Disease in NZB/W Mice

References

• Howie J. B., Holyer B. J. The immunology and pathology of NZB mice. Adv. Immunol 1968; 9: 215–266
   PubMedGoogle Scholar
• Holmes M. C., Burnet F. M. The natural history of autoimmune disease in NZB mice. Ann. Int. Med. 1963; 59: 265–276
   PubMed Web of Science ®Google Scholar
• Lambert P. H., Dixon F. J. Pathogenesis of the glomerulonephritis of NZB/W mice. J. Exp. Med. 1968; 127: 507–522
   PubMed Web of Science ®Google Scholar
• Warner N. L. Genetic aspects of autoimmune disease in animals. Autoimmunity: Genetic. Immunologic, Virologic and Clinical Aspects, N. Talal. Academic Press, Inc., New York 1977; 404–456
   Google Scholar
• Dubois E. L., Horowitz R. E., Demopoulos H. B., Teplitz R. NZB/NZW mice as a model of systemic lupus erythematosus. J. Am. Med. Assoc 1966; 195: 285–289
   PubMed Web of Science ®Google Scholar
• Roubinian J. R., Papoian R., Talal N. Androgenic hormones modulate autoantibody responses and improve survival in murine lupus. J. Clin. Invest. 1977; 59: 1066–1070
   PubMed Web of Science ®Google Scholar
• Roubinian J. R., Talal N., Greenspan J. S., Goodman J. R., Siiteri P. K. Effect of castration and sex hormone treatment on survival, anti-nucleic acid antibodies, and glomerulonephritis in NZB/NZW F1 mice. J Exp. Med. 1978; 147: 1568–1583
   PubMed Web of Science ®Google Scholar
• Roubinian J. R., Talal N., Siiteri P. K., Sadakian J. A. Sex hormone modulation of autoimmunity in NZB/NZW mice. Arthritis Rheum. 1979; 22: 1162–1168
   PubMed Web of Science ®Google Scholar
• Roubinian J. R., Talal N., Greenspan J. S., Goodman J. R., Siiteri P. K. Delayed androgen treatment prolongs survival in murine lupus. J. Clin. Invest. 1979; 63: 902–911
   PubMed Web of Science ®Google Scholar
• Lucas J. A., Ahmed S. A., Casey M. L., MacDonald P. C. Prevention of autoantibody formation and prolonged survival in New Zealand Black/New Zealand White F1 mice fed dehydroisoandrosterone. J. Clin. Invest. 1985; 75: 2091–2093
   PubMed Web of Science ®Google Scholar
• Casali P., Burastero S. E., Nakamura M., Inghirami G., Notkins A. L. Human lymphocytes making rheumatoid factor and antibody to ssDNA belong to Leu-1+ B-cell subset. Science 1987; 236: 77–81
   PubMed Web of Science ®Google Scholar
• Hayakawa K., Hardy R. R., Honda M., Herzenberg L. A., Steinberg A. D., Herzenberg L. A. Ly-1 B cells: functionally distinct lymphocytes that secrete IgM autoantibodies. Proc. Natl. Acad. Sci.(USA) 1984; 81: 2494–2498
   PubMed Web of Science ®Google Scholar
• Stall A. M., Farinas M. C, Tarlinton D. M., Lalor P. A., Herzenberg L. A., Strober S., Herzenberg L. A. Ly-1 B cell clones similar to human chronic lymphocytic leukemias routinely develop in older normal mice and young autoimmune (New Zealand Black-related) animals. Proc. Natl. Acad. Sci. (USA) 1988; 85: 7312–7316
   PubMed Web of Science ®Google Scholar
• Engleman E. G., Sonnenfeld G., Dauphinee M., Greenspan J. S., Talal N., McDevitt H. O., Merigan T. C. Treatment of NZB/NZW F1 hybrid mice with mycobacterium bovis strain BCG or type II interferon preparations accelerates autoimmune disease. Arthritis-Rheum. 1981; 24: 1396–1402
   PubMed Web of Science ®Google Scholar
• Heremans H., Billiau A., Colombatti A., Hilgers J., De Somer P. Interferon treatment of NZB mice: accelerated progression of autoimmune disease. Infect. Immun. 1978; 21: 925–930
   PubMed Web of Science ®Google Scholar
• Ishida H., Muchamuel T., Sakaguchi S., Andrade S., Menon S., Howard M. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F, mice. J. Exp. Med. 1994; 179: 305–310
   PubMed Web of Science ®Google Scholar
• Ishida H., Hastings R., Snipes L. T., Howard M. Modified immunological status of anti-IL-10 treated mice. Cell. Immunol. 1993; 148: 371–384
   PubMed Web of Science ®Google Scholar
• Jacob C. O., McDevitt H. O. Tumour necrosis factor-α in murine autoimmune lupus' nephritis. Nature (London) 1988; 331: 356–358
   PubMed Web of Science ®Google Scholar
• Gordon C., Ranges G. E., Greenspan J. S., Wofsy D. Chronic therapy with recombinant tumor necrosis factor-α in autoimmune NZB/NZW F1 mice. Clin. Immunol. Immunopathol 1989; 52: 421–434
   PubMedGoogle Scholar
• Daynes R. A., Dudley D. J., Araneo B. A. Regulation of murine lymphokine production in vivo II. Dehydroepiandrosterone is a natural enhancer of inter-leukin 2 synthesis by helper T cells. Eur. J. Immunol. 1990; 20: 793–802
   PubMed Web of Science ®Google Scholar
• Araneo B. A., Dowell T., Diegel M., Daynes R. A. Dihydrotestosterone exerts a depressive influence on the production of interleukin-4 (IL-4), IL-5, and γ-interferon, but not IL-2 by activated murine T cells. Blood 1991; 78: 688–699
   PubMed Web of Science ®Google Scholar
• Suzuki T., Suzuki N., Daynes R. A., Engleman E. G. Dehydroepiandrosterone enhances IL-2 production and cytotoxic effector function of human T cells. Clin. Immunol, and Immunopathol. 1991; 61: 202–211
   PubMedGoogle Scholar
• Danenberg H. D., Alpert G., Lustig S., Ben-Nathan D. Dehydroepiandrosterone protects mice from endotoxin toxicity and reduces tumor necrosis factor production. Antimicrob. Agents and Chem. 1992; 36: 2275–2279
   PubMed Web of Science ®Google Scholar
• Araneo B. A., Woods M. L., Daynes R. A. Reversal of the immunosenescent phenotype by dehydroepiandrosterone: hormone treatment provides an adjuvant effect on the immunization of aged mice with recombinant hepatitis B surface antigen. J. Infect. Dis. 1993; 167: 830–840
   PubMed Web of Science ®Google Scholar
• Daynes R. A., Araneo B. A. Prevention and reversal of some age-associated changes in immunologic responses by supplemental dehydroepiandrosterone sulfate therapy. Aging: Immunol. Infect. Dis. 1992; 3: 135–154
   Google Scholar
• Daynes R. A., Araneo B. A., Ershler W. B., Maloney C., Li G., Ryu S. Altered regulation of IL-6 production with normal aging. Possible linkage to the age-associated decline in dehydroepiandrosterone and its sulfated derivative. J. Immunol. 1993; 150: 5219–5230
   PubMed Web of Science ®Google Scholar
• Mercolino T. J., Arnold L. W., Hawkins L. A., Haughton G. Normal mouse peritoneum contains a large population of LY-1+ (CD5) B cells that recognize phosphatidyl choline. J. Exp. Med. 1988; 168: 687–698
   PubMed Web of Science ®Google Scholar
• Spencer N. F. L., Norton S. D., Harrison L. L., Li G., Daynes R. A. Dysregulation of IL-10 production with aging: possible linkage to the age-associated decline in DHEA and its sulfated derivative. Exp. Gerontol. 1996; 31: 393–408
   PubMed Web of Science ®Google Scholar
• Hayakawa K., Hardy R. R. Normal, autoimmune, and malignant CD5+ B cells: the Ly-1 B lineage?. Ann. Rev. Immunol. 1988; 6: 197–218
   PubMed Web of Science ®Google Scholar
• Hennebold J. D., Daynes R. A. Regulation of macrophage dehydroepiandrosterone sulfate metabolism by inflammatory cytokines. Endocrinology 1994; 135: 67–75
   PubMed Web of Science ®Google Scholar
• van Vollenhoven R. F., Engleman E. G., McGuire J. L. An open study of dehydroepiandrosterone in systemic lupus erythematosus. Arthritis and Rheumatism 1994; 37: 1305–1310
   PubMed Web of Science ®Google Scholar
• van Vollenhoven R. F., Engleman E. G., McGuire J. L. Dehydroepiandrosterone in systemic lupus erythematosus. Results of a double-blind, placebo-controlled, randomized clinical trial. Arthritis and Rheumatism 1995; 38: 1826–1831
   PubMed Web of Science ®Google Scholar
• Llorente L., Zou W., Levy Y., Richaud-Patin Y., Wijdenes J., Alcocer-Varela J., Morel-Fourrier B., Brouet J., Alarcon-Segovia D., Galanaud P., Emilie D. Role of Interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J. Exp. Med. 1995; 181: 839–844
   PubMed Web of Science ®Google Scholar
• Wofsy D., Seaman W. E. Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4. J. Exp. Med. 1985; 161: 378–391
   PubMed Web of Science ®Google Scholar
• Okada T., Abe M., Takiura F., Hirose S., Shirai T. Distinct surface phenotypes of B cells responsible for spontaneous production of IgM and IgG anti-DNA antibodies in autoimmune-prone NZB x NZW F1 mice. Autoimmunity 1990; 7: 109–120
   PubMed Web of Science ®Google Scholar
• Sagawa A. [Analysis of anti-DNA antibody in sera from patients with systemic lupus erythematosus by isoelectric focusing with respect to autoantibody isotype and immune complex]. Hokkaido Igaku Zasshi 1992; 67: 67–80
   PubMedGoogle Scholar
• Sarvas H., Gripenberg M., Leirisalo-Repo M. Anti-DNA antibodies: the choice of assays for routine diagnostic work. Acta. Pathol. Microbiol. Immunol. Scand. 1985; 93: 8–13
   Google Scholar
• Dang H., Harbeck R. J. A comparison of anti-DNA antibodies from serum and kidney eluates of NZB x NZW F1 mice. J. Clin. Lab Immunol. 1982; 9: 139–145
   PubMedGoogle Scholar
• Bresnihan B., Hale G. M., Bunn C. C., Hughes G. R. Immunoglobulin classes in skin basement membrane in systemic lupus erythematosus: clinical significance and comparison with classes of serum anti-DNA antibodies. Ann. Rheum. Dis. 1979; 38: 351–355
   PubMed Web of Science ®Google Scholar
• Talal N. Natural history of murine lupus. Arth. Rheum. 1978; 21: S58–S63
   Google Scholar
• Maruyama N., Furukawa F., Nakai Y., Sasaki Y., Ohta K., Ozaki S., Hirose S., Shirai T. Genetic studies of autoimmunity in New Zealand mice. IV. Contribution of NZB and NZW genes to the spontaneous occurrence of retroviral gp70 immune complexes in (NZB/NZW) F1 hybrid and the correlation to renal disease. J. Immunol 1983; 130: 740–746
   PubMed Web of Science ®Google Scholar
• Taurog J. D., Moutsopoulos H. M., Rosenberg Y. J., Chused T. M., Steinberg A. D. CBA/N X-linked B-cell defect prevents NZB B-cell hyperactivity in F1 mice. J. Exp. Med. 1979; 150: 31–43
   PubMed Web of Science ®Google Scholar
• Datta S. K., Gavalchin J. Origins of pathogenic anti-DNA idiotypes in the NZB X SWR model of lupus nephritis. Ann. N. Y. Acad. Sci 1986; 475: 47–58
   PubMed Web of Science ®Google Scholar
• Hirose S., Sekigawa I., Ozaki S., Sato H., Shirai T. Genetic regulation of hypergammaglobulinaemia and the correlation to autoimmune traits in (NZB/NZW) F1 hybrid. Clin. Exp. Immunol 1984; 58: 694–702
   PubMed Web of Science ®Google Scholar
• O'Garra A., Chang R., Go N., Hastings R., Haughton G., Howard M. Ly-1 B (B-1) cells are the main source of B cell derived interleukin 10. Eur. J. Immunol 1992; 22: 711–717
   PubMed Web of Science ®Google Scholar
• Moore K. W., O'Garra A., De Waal M. R., Vieira P., Mossman T. Interleukin-10. Ann. Rev. Immunol 1993; 11: 165–190
   PubMed Web of Science ®Google Scholar